Merck MRK
today announced findings from three studies investigating the use of
KEYTRUDA® (pembrolizumab), the company's anti-PD-1 therapy,
in combination with three other immunotherapies – epacadostat, IMLYGICTM
(talimogene laherparepvec), and ipilimumab – in patients with advanced
melanoma. The findings, which were featured in separate oral
presentations today at the Society for Melanoma Research 2015
International Congress (SMR) in San Francisco, showed robust anti-tumor
activity with KEYTRUDA in all three combinations studied.
"We have demonstrated the benefit of KEYTRUDA as a single agent in
advanced/metastatic melanoma and we are now also looking to identify
potential combinations for patients with this devastating disease," said
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in